Forum Financial Management LP Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Forum Financial Management LP boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,525 shares of the biopharmaceutical company's stock after purchasing an additional 4,867 shares during the quarter. Forum Financial Management LP's holdings in Gilead Sciences were worth $2,173,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its position in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Gilead Sciences by 3.1% in the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after acquiring an additional 1,058,331 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares in the last quarter. Norges Bank bought a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $1,789,254,000. Finally, Invesco Ltd. increased its position in Gilead Sciences by 12.9% during the 4th quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company's stock worth $1,041,741,000 after purchasing an additional 1,292,399 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 0.2 %

Shares of Gilead Sciences stock traded down $0.17 on Wednesday, hitting $105.34. The company had a trading volume of 3,343,824 shares, compared to its average volume of 7,495,909. The stock has a 50 day moving average of $109.17 and a 200-day moving average of $97.82. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The stock has a market capitalization of $131.17 billion, a price-to-earnings ratio of 284.70, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 3.00%. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on GILD shares. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday. They set an "overweight" rating and a $125.00 price target for the company. The Goldman Sachs Group boosted their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Finally, Piper Sandler raised their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Ten equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $106.92.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the transaction, the chief financial officer now directly owns 168,174 shares of the company's stock, valued at approximately $17,893,713.60. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 302,785 shares of company stock worth $30,540,875 in the last ninety days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.